1. Ivashkin V.T, Maev I.V, Trukhmanov A. S. i soavt. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniyu gastroezofageal'noi reflyuksnoi bolezni // Ros. zhurn. gastroenterol. gepatol. koloproktol. - 2017. - T. 27, № 4. - S. 75-95. Ivashkin V. T., Mayev I. V., A.s. Trukhmanov I…, Baranskaya Y. K., et al. Diagnostics and treatment of gastroesophageal ref lux disease: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75-95. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-75-95
2. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. - 2019. - Vol. 90, № 3. - R. 335-359.
3. Gatenby P., Caygill C., Wall C., et al. Lifetime risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. World J Gastroenterol. - 2014.-Vol. 20, № 28.-P. 9611-9617.
4. Falk G. W. Barrett’s oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol. - 2015. - Vol. 29, № 1. - R. 125-138.
5. Whitson M.J., Falk G. W. Predictors of progression to high-grade dysplasia or adenocarcinoma in Barrett’s esophagus. Gastroenterol Clin North Am. - 2015. - Vol. 44, № 2. - P. 299-315.
6. Reid B.J., Levine D. S., Longton G., et al. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. - 2000. - Vol. 95, № 7. - P. 1669-1676.
7. Duits L.C., Phoa K. N., Curvers W. L., et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. - 2015. - Vol. 64, № 5. - P. 700-706.
8. de Jonge P. J., van Blankenstein M., Looman C. W., et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. - 2010. - Vol. 59, № 8. - P. 1030-1036.
9. Rugge M., Zaninotto G., Parente P., et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg. - 2012. - Vol. 256, № 5. - P. 788-794.
10. Sanghi V., Thota P. N. Barrett’s esophagus: novel strategies for screening and surveillance. Ther Adv Chronic Dis. - 2019. - Vol. 26, № 10. - P. 2040622319837851.
11. Pandey G., Mulla M., Lewis W. G., et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett’s esophagus. Endoscopy. - 2018. - Vol. 50, № 10. P. 953-960.
12. Caspa Gokulan R., Garcia-Buitrago M.T., Zaika A. I. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochim Biophys Acta Rev Cancer. - 2019. - Vol. 1872, № 1. - P. 37-48.
13. Abdel-Latif M.M., Duggan S., Reynolds J. V., Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. - 2009. - Vol. 9. - P. 396-404.
14. Que J., Garman K. S., Souza R. F., Spechler S. J. Pathogenesis and cells of origin of Barrett’s esophagus. Gastroenterology. - 2019. - Vol. 157, № 2. - R. 349-364.
15. Reid B. J. Early events during neoplastic progression in Barrett’s esophagus. Cancer Biomark. -2010. - Vol. 9, № 1-6. - P. 307-24.
16. Kaz A.M., Grady W. M., Stachler M. D., Bass A. J. Genetic and epigenetic alterations in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. -2015. - Vol. 44, № 2. - P. 473-489.
17. Contino G., Vaughan T. L., Whiteman D., Fitzgerald R. C. The evolving genomic landscape of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. - 2017. - Vol. 153, № 3. - R. 657-673.e1.
18. Dulak A.M., Stojanov P., Peng S. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. - 2013.-Vol. 45, № 5.-R. 478-486.
19. Ross-Innes C.S., Becq J., Warren A., et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat Genet. 2015. - Vol. 47, № 9. - P. 1038-1046.
20. Gregson E.M., Bornschein J., Fitzgerald R. C. Genetic progression of Barrett’s oesophagus to oesophageal adenocarcinoma. Br J Cancer. - 2016. - Vol. 115, № 4. - P. 403-410.
21. Integrated genomic characterization of oesophageal carcinoma. Nature. - 2017. - Vol. 541, № 7636. - P. 169-175.
22. Nones K., Waddell N., Wayte N., et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. - 2014. - Vol. 5. - P. 5224.
23. Secrier M., Li X., de Silva N., et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. - 2016. - Vol. 48, № 10. - R. 1131-1141.
24. Fang M., Lew E., Klein M., et al. DNA abnormalities as marker of risk for progression of Barrett’s esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fi xed tissues. Am J Gastroenterol. - 2004. - Vol. 99, № 10. - P. 1887-1894.
25. Galipeau P.C., Li X., Blount P. L., Maley C. C., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. - 2007. - Vol. 4, № 2. - P. e67.
26. Altaf K., Xiong J. J., la Iglesia D. et al. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett’s oesophagus. Br J Surg. - 2017. Vol. 104, № 5. - P. 493-502.
27. Chumakov P. M. Belok r53 i ego universal'nye funktsii v mnogokletochnom organizme // Uspekhi biol. Khimii. - 2007. - T. 47. - C. 3-52. Chumakov P. M. Protein p53 and its universal functions in a multicellular organism. Uspekhi biol. Chemistry. 2007, vol. 47, pp. 3-52.
28. Stachler M.D., Camarda N. D., Deitrick C., et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. - 2018. - Vol. 155. - P. 156-167.
29. Kastelein F., Biermann K., Steyerberg E. W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut. - 2013. - Vol. 62, № 12. - P. 1676-1683.
30. Younes M., Brown K., Lauwers G. Y., et al. P53 protein accumulation predicts malignant progression in Barrett’s metaplasia: a prospective study of 275 patients. Histopathology. - 2017. - Vol.71. - P. 27-33.
31. Davelaar A.L., Calpe S., Lau L., et al. Aberrant TP53 detected by combining immunohistochemistry and DNAFISH improves Barrett’s esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer. - 2015. - Vol. 54, № 2. - P. 82-90.
32. di Pietro M., Boerwinkel D. F., Shariff M. K., et al. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett’s oesophagus. Gut. - 2015. - Vol. 64, № 1. - P. 49-56.
33. Snyder P., Dunbar K., Cipher D., et al. Aberrant p53 immunostaining in Barrett’s esophagus predicts neoplastic progression: Systematic review and meta-analyses. Dig Dis Sci. - 2019. - Vol. 64, № 5. - R. 1089-1097.
34. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. - 2014. - Vol. 63. - P. 7-42.
35. Khara H.S., Jackson S. A., Nair S., et al. Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifi cations of Barrett’s esophagus. J Gastrointest Cancer. - 2014. - Vol. 45, № 2. - P. 137-145.
36. Das A., Callenberg K. M., Styn M. A., Jackson S. A. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability. Endosc Int Open. - 2016. - Vol. 4, № 5. - P. E549-559.
37. Martinez P., Timmer M. R., Lau C. T., et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat Commun. - 2016. - Vol. 7. - P. 12158.
38. Kailasam A., Mittal S. K., Agrawal D. K. Epigenetics in the pathogenesis of esophageal adenocarcinoma. Clin Transl Sci. - 2015. - Vol. 8, № 4. - P. 394-402.
39. Nieto T., Tomlinson C. L., Dretzke J., et al. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett’s oesophagus to oesophageal adenocarcinoma. BMJ Open. - 2018. - Vol. 8, № 6. - P. e020427.
40. Ross-Innes C.S., Chettouh H., Achilleos A., et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. - 2017. - Vol. 2. - P. 23-31.
41. Katz-S ummercorn A., Anand S., Ingledew S., et al. Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett’s oesophagus. J Pathol Clin Res. - 2017. - Vol. 3, № 4. - P. 258-267.